Strides Pharma Science Limited (STAR.BO)
INR 702.0
(1.56%)
INR 702.0
(1.56%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 58.39 Billion INR | -12.03% |
| 2022 | 66.38 Billion INR | -4.84% |
| 2021 | 69.75 Billion INR | -0.56% |
| 2020 | 70.15 Billion INR | 14.03% |
| 2019 | 61.51 Billion INR | -22.91% |
| 2018 | 79.79 Billion INR | 18.95% |
| 2017 | 67.08 Billion INR | -18.92% |
| 2016 | 82.74 Billion INR | 10.98% |
| 2015 | 74.55 Billion INR | 200.58% |
| 2014 | 24.8 Billion INR | 18.18% |
| 2013 | 20.99 Billion INR | -56.25% |
| 2012 | 47.97 Billion INR | -10.56% |
| 2011 | 53.64 Billion INR | 19.38% |
| 2010 | 44.93 Billion INR | 38.94% |
| 2009 | 32.34 Billion INR | 38.95% |
| 2008 | 23.27 Billion INR | 14.44% |
| 2007 | 20.33 Billion INR | 65.75% |
| 2006 | 12.26 Billion INR | 31.1% |
| 2005 | 9.35 Billion INR | 71.2% |
| 2004 | 5.46 Billion INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 59.89 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 58.39 Billion INR | -12.03% |
| 2023 Q4 | 58.39 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 63.37 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 66.38 Billion INR | -4.84% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 68.44 Billion INR | 0.0% |
| 2022 Q4 | 66.38 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 69.75 Billion INR | -0.56% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 68.43 Billion INR | 0.0% |
| 2021 Q4 | 69.75 Billion INR | 0.0% |
| 2020 Q4 | 70.15 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 66.32 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 70.15 Billion INR | 14.03% |
| 2019 Q4 | 61.51 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 59.88 Billion INR | 0.0% |
| 2019 FY | 61.51 Billion INR | -22.91% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 79.79 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 72.35 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 79.79 Billion INR | 18.95% |
| 2017 Q4 | 67.08 Billion INR | 0.0% |
| 2017 FY | 67.08 Billion INR | -18.92% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 84.75 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 82.74 Billion INR | 0.0% |
| 2016 Q2 | 77.82 Billion INR | 0.0% |
| 2016 FY | 82.74 Billion INR | 10.98% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q4 | 74.55 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 42.03 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 74.55 Billion INR | 200.58% |
| 2014 FY | 24.8 Billion INR | 18.18% |
| 2014 Q4 | 24.8 Billion INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 20.99 Billion INR | -56.25% |
| 2012 FY | 47.97 Billion INR | -10.56% |
| 2011 FY | 53.64 Billion INR | 19.38% |
| 2010 FY | 44.93 Billion INR | 38.94% |
| 2009 FY | 32.34 Billion INR | 38.95% |
| 2008 FY | 23.27 Billion INR | 14.44% |
| 2007 FY | 20.33 Billion INR | 65.75% |
| 2006 FY | 12.26 Billion INR | 31.1% |
| 2005 FY | 9.35 Billion INR | 71.2% |
| 2004 FY | 5.46 Billion INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Ajanta Pharma Limited | 46.38 Billion INR | -25.9% |
| Amrutanjan Health Care Limited | 3.66 Billion INR | -1491.775% |
| Sigachi Industries Limited | 6.94 Billion INR | -741.274% |
| Bal Pharma Limited | 3.2 Billion INR | -1722.708% |
| Ind-Swift Laboratories Limited | 11.65 Billion INR | -401.221% |
| Medico Remedies Limited | 961.95 Million INR | -5970.728% |
| Lasa Supergenerics Limited | 1.5 Billion INR | -3770.753% |
| Venus Remedies Limited | 6.26 Billion INR | -831.633% |
| Sun Pharma Advanced Research Company Limited | 5.15 Billion INR | -1033.845% |
| Alpa Laboratories Limited | 1.82 Billion INR | -3097.733% |
| Nectar Lifesciences Limited | 21.91 Billion INR | -166.527% |
| Shilpa Medicare Limited | 30.93 Billion INR | -88.793% |
| Aarti Drugs Limited | 24.32 Billion INR | -140.086% |
| Lupin Limited | 239.97 Billion INR | 75.665% |
| Aurobindo Pharma Limited | 450.71 Billion INR | 87.043% |
| Zydus Lifesciences Limited | 292.8 Billion INR | 80.056% |
| Windlas Biotech Limited | 6.26 Billion INR | -832.561% |
| Suven Life Sciences Limited | 2.84 Billion INR | -1949.737% |
| Eris Lifesciences Limited | 70.48 Billion INR | 17.153% |
| Valiant Laboratories Limited | 3.42 Billion INR | -1604.106% |
| J. B. Chemicals & Pharmaceuticals Limited | 39.94 Billion INR | -46.208% |
| Solara Active Pharma Sciences Limited | 23.5 Billion INR | -148.399% |
| Ipca Laboratories Limited | 111.01 Billion INR | 47.396% |
| Bliss GVS Pharma Limited | 12.13 Billion INR | -381.086% |
| Achyut Healthcare Limited | 309.52 Million INR | -18767.011% |
| Sun Pharmaceutical Industries Limited | 854.62 Billion INR | 93.167% |
| Bajaj HealthCare Limited | 7.65 Billion INR | -663.239% |
| RPG Life Sciences Limited | 5.12 Billion INR | -1038.642% |
| Mankind Pharma Limited | 119.63 Billion INR | 51.186% |
| Laurus Labs Limited | 83.87 Billion INR | 30.372% |
| Piramal Pharma Limited | 153.11 Billion INR | 61.861% |
| Syncom Formulations (India) Limited | 4.04 Billion INR | -1343.112% |
| Torrent Pharmaceuticals Limited | 150.61 Billion INR | 61.226% |
| Alembic Pharmaceuticals Limited | 64.45 Billion INR | 9.399% |
| Glenmark Pharmaceuticals Limited | 143.58 Billion INR | 59.329% |
| Unichem Laboratories Limited | 31.69 Billion INR | -84.258% |
| Sequent Scientific Limited | 15.4 Billion INR | -279.11% |
| Novartis India Limited | 9.24 Billion INR | -531.373% |
| Wanbury Limited | 3.43 Billion INR | -1600.108% |
| Suven Pharmaceuticals Limited | 22.54 Billion INR | -159.074% |
| Wockhardt Limited | 76.49 Billion INR | 23.653% |
| Themis Medicare Limited | 5.66 Billion INR | -931.0% |
| Jagsonpal Pharmaceuticals Limited | 2.17 Billion INR | -2590.164% |
| Jubilant Pharmova Limited | 115.48 Billion INR | 49.433% |
| Glenmark Life Sciences Limited | 28.5 Billion INR | -104.874% |
| Dr. Reddy's Laboratories Limited | 387.51 Billion INR | 84.93% |
| Divi's Laboratories Limited | 154.7 Billion INR | 62.251% |
| NATCO Pharma Limited | 69.06 Billion INR | 15.443% |
| Gufic Biosciences Limited | 10.92 Billion INR | -434.511% |
| IOL Chemicals and Pharmaceuticals Limited | 22.44 Billion INR | -160.192% |
| Ind-Swift Limited | 6.54 Billion INR | -792.286% |
| Procter & Gamble Health Limited | 7.94 Billion INR | -635.152% |
| FDC Limited | 24.68 Billion INR | -136.61% |
| Krebs Biochemicals & Industries Limited | 1.78 Billion INR | -3177.544% |
| Granules India Limited | 55.2 Billion INR | -5.774% |
| Medicamen Biotech Limited | 2.94 Billion INR | -1882.788% |
| Alkem Laboratories Limited | 155.74 Billion INR | 62.505% |
| AstraZeneca Pharma India Limited | 10.78 Billion INR | -441.707% |
| Biofil Chemicals and Pharmaceuticals Limited | 470.82 Million INR | -12303.186% |
| Brooks Laboratories Limited | 904.45 Million INR | -6356.663% |
| Megasoft Limited | 3.65 Billion INR | -1495.999% |
| ZIM Laboratories Limited | 4.46 Billion INR | -1206.952% |
| Neuland Laboratories Limited | 18.32 Billion INR | -218.666% |
| Morepen Laboratories Limited | 12.93 Billion INR | -351.572% |
| Hikal Limited | 24.87 Billion INR | -134.798% |
| Indoco Remedies Limited | 21.44 Billion INR | -172.284% |
| Aarti Pharmalabs Limited | 25.82 Billion INR | -126.163% |
| Kilitch Drugs (India) Limited | 2.4 Billion INR | -2332.607% |
| Mangalam Drugs & Organics Limited | 3.33 Billion INR | -1651.449% |
| Hester Biosciences Limited | 6.62 Billion INR | -781.676% |